US · IONS · BIOTECHNOLOGY
Ionis Pharmaceuticals, Inc. (IONS) intrinsic value and stock valuation
$26.58as of 2026-11-21 · Mkt cap 9.01B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Ionis Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values IONS with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from IONS’s statements →
Ionis Pharmaceuticals, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Revolution Medicines, Inc. (RVMD) $161.20
- Roivant Sciences Ltd. (ROIV) $38.66
- Moderna, Inc. (MRNA) $195.00
- Guardant Health, Inc. (GH) $145.83
- BridgeBio Pharma, Inc. (BBIO) $76.03
- Ascendis Pharma A/S (ASND) $252.73
- Exelixis, Inc. (EXEL) $64.63
- BioMarin Pharmaceutical Inc. (BMRN) $60.41
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $944M | $705.1M | $787.7M | $587.4M | $810.5M |
| Operating income | -$-382M | -$-475.08M | -$-353.73M | -$-410.19M | -$-30.19M |
| Net income | -$-381M | -$-453.9M | -$-366.29M | -$-269.72M | -$-28.6M |
| EPSd | -$-2.38M | -$-3.04M | -$-2.56M | -$-1.9M | -$-202.81K |
| Operating cash flow | -$-268.58M | -$-500.95M | -$-307.51M | -$-274.37M | $30.8M |
| Capital expenditure | -$-51.44M | -$-45.28M | -$-28.01M | -$-20.1M | -$-17.9M |
| Free cash flow | -$-320.03M | -$-546.23M | -$-335.52M | -$-294.47M | $12.9M |
| Total assets | $3.52B | $3B | $2.99B | $2.53B | $2.61B |
| Total debt | $2.61B | $1.42B | $1.45B | $1.37B | $1.25B |
| Net debt | $2.24B | $1.17B | $1.05B | $1.09B | $381.9M |
| Total equity | $489.1M | $588.4M | $386.7M | $572.9M | $771.7M |
| Cash and short-term investments | $2.68B | $2.3B | $2.33B | $2B | $2.13B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $944M | $705.1M | $787.7M | $587.4M | $810.5M |
| Cost of revenue | $16M | $11.2M | $9.13M | $14.1M | $10.8M |
| Gross profit | $928M | $693.9M | $778.5M | $573.3M | $799.6M |
| Research and development expenses | $916M | $901.5M | $899.6M | $833M | $643M |
| Selling, general and administrative expenses | $394M | $267.5M | $232.6M | $150.3M | $170.9M |
| Other expenses | $0.00 | -$-30K | $20K | $150K | $15.9M |
| Operating expenses | $1.31B | $1.17B | $1.13B | $983.4M | $829.8M |
| Cost and expenses | $1.33B | $1.18B | $1.14B | $997.6M | $840.6M |
| Interest income | $97.8M | $107M | $89M | $25.3M | $10M |
| Interest expense | $90.5M | $90.5M | $81.5M | $8.12M | $9.35M |
| Depreciation and amortization | $20.3M | $22M | $22.5M | $22.1M | $19.6M |
| Ebitda | -$-286.75M | -$-353.72M | -$-235.87M | -$-227.76M | -$-5.19M |
| Operating income | -$-382M | -$-475.08M | -$-353.73M | -$-410.19M | -$-30.19M |
| Total other income/expenses, net | $2M | $15M | $19.8M | $152.2M | $1.04M |
| Income before tax | -$-380M | -$-460.07M | -$-333.96M | -$-257.99M | -$-29.15M |
| Income tax expense | $1M | -$-6.17M | $32.3M | $11.7M | -$-550K |
| Net income | -$-381M | -$-453.9M | -$-366.29M | -$-269.72M | -$-28.6M |
| Weighted average shares outstanding | $160M | $149.5M | $143M | $141.9M | $141M |
| Weighted average diluted shares outstanding | $160M | $149.5M | $143.2M | $141.9M | $141M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $2.68B | $2.3B | $2.33B | $2B | $2.13B |
| Net receivables | $66M | $92.2M | $97.8M | $25.5M | $61.9M |
| Inventory | $10.1M | $12.5M | $7.44M | $22M | $24.8M |
| Total current assets | $2.99B | $2.62B | $2.64B | $2.2B | $2.35B |
| Property, plant and equipment, net | $362M | $256.1M | $242.9M | $255.8M | $196M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $29M |
| Long-term investments | $52.2M | $41M | $43M | $40.4M | $32.3M |
| Total non-current assets | $533.2M | $383.4M | $348.2M | $331.2M | $266.6M |
| Total assets | $3.52B | $3B | $2.99B | $2.53B | $2.61B |
| Accounts payable | $28.1M | $43M | $26M | $17.9M | $11.9M |
| Short-term debt | $453.2M | $9.28M | $53.2M | $7.54M | $3.53M |
| Deferred revenue | $73.8M | $79M | $151.1M | $90.6M | $97.7M |
| Total current liabilities | $781.6M | $309.3M | $448.1M | $311.6M | $240.6M |
| Long-term debt | $2.16B | $1.41B | $1.4B | $1.36B | $1.25B |
| Deferred revenue, non-current | $92M | $156.5M | $241.2M | $287.8M | $351.9M |
| Total non-current liabilities | $2.25B | $2.11B | $2.16B | $1.65B | $1.6B |
| Capital lease obligations | $262.4M | $161.8M | $170.9M | $178.9M | $19.4M |
| Total liabilities | $3.03B | $2.42B | $2.6B | $1.96B | $1.84B |
| Common stock | $160K | $160K | $140K | $140K | $140K |
| Retained earnings | -$-2.63B | -$-2.25B | -$-1.8B | -$-1.43B | -$-1.16B |
| Accumulated other comprehensive income (loss) | -$-25.28M | -$-30.81M | -$-32.65M | -$-57.48M | -$-32.67M |
| Total equity | $489.1M | $588.4M | $386.7M | $572.9M | $771.7M |
| Total investments | $2.36B | $2.1B | $1.98B | $1.76B | $1.3B |
| Total debt | $2.61B | $1.42B | $1.45B | $1.37B | $1.25B |
| Net debt | $2.24B | $1.17B | $1.05B | $1.09B | $381.9M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-381.39M | -$-453.9M | -$-366.29M | -$-269.72M | -$-28.6M |
| Depreciation and amortization | $22.7M | $19.7M | $22.5M | $22.1M | $19.6M |
| Stock-based compensation | $133.9M | $130.2M | $105.8M | $100.3M | $120.7M |
| Change in working capital | -$-51.22M | -$-209.39M | -$-77.26M | $7.57M | -$-113.82M |
| Accounts receivable | $26.1M | $5.59M | -$-72.06M | $36.4M | $5.05M |
| Inventory | -$-13.67M | -$-5.07M | -$-6.39M | $2.77M | -$-2.84M |
| Accounts payable | -$-15.36M | $16M | $8.12M | $1.09M | -$-6M |
| Net cash provided by operating activities | -$-268.58M | -$-500.95M | -$-307.51M | -$-274.37M | $30.8M |
| Investments in property, plant and equipment | -$-51.44M | -$-45.28M | -$-23.8M | -$-20.1M | -$-17.9M |
| Acquisitions, net | $0.00 | $0.00 | $20K | $254.1M | $5.95M |
| Net cash used for investing activities | -$-277.78M | -$-134.03M | -$-214.13M | -$-262.64M | $194.9M |
| Common stock issued | $192.6M | $522.7M | $49.4M | $6.37M | $85.7M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $675.8M | $478.1M | $644.1M | -$-55.3M | $245.9M |
| Net change in cash | $130.2M | -$-157.19M | $122.8M | -$-592.72M | $471.5M |
| Cash at end of period | $372.3M | $242.1M | $399.3M | $276.5M | $869.2M |
| Operating cash flow | -$-268.58M | -$-500.95M | -$-307.51M | -$-274.37M | $30.8M |
| Capital expenditure | -$-51.44M | -$-45.28M | -$-28.01M | -$-20.1M | -$-17.9M |
| Free cash flow | -$-320.03M | -$-546.23M | -$-335.52M | -$-294.47M | $12.9M |
Line items
Line items
Line items
About Ionis Pharmaceuticals, Inc.
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
- CEO
- Brett Monia
- Employees
- 1.4K
- Beta
- 0.36
Explore
Frequently asked questions
What is the intrinsic value of Ionis Pharmaceuticals, Inc. (IONS)?
Ionis Pharmaceuticals, Inc. (IONS) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is IONS undervalued?
IONS trades at a price of $26.58 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.